Taurine
Taurine is a conditionally essential sulfur-containing amino acid (2-aminoethanesulfonic acid) found naturally in the diet (meat, seafood) and synthesized endogenously; it is marketed as an ancillary ergogenic supplement and is a common energy-drink ingredient. It is one of the better-tolerated ergogenic compounds: pooled randomized-trial data show no systematic pattern of serious adverse effects at supplemental intakes up to ~3 g/day, and a 2008 risk assessment could not identify a NOAEL/LOAEL because harms were not observed, instead setting an Observed Safe Level of 3 g/day. The main caution is not taurine toxicity per se but context: taurine is usually consumed inside caffeine-containing energy drinks, where caffeine (not taurine) drives tachycardia, arrhythmia, hypertension, sleep disruption, and, with alcohol co-ingestion, risky behavior. Taurine itself modestly lowers blood pressure and heart rate, which can compound the effect of other hypotensive or bradycardic agents. Long-term safety of intakes above 3 g/day is not well characterized, data in pregnancy/lactation and in significant kidney or liver disease are inadequate, and its actual performance benefit as a standalone agent is small and confounded by the other ingredients it is typically taken with. This is educational harm-reduction information, not medical advice.
Mechanism of action
Pharmacokinetics
Short: plasma elimination half-life ~1.0 ± 0.3 hours after a single 4 g oral dose in healthy fasting adults (PMID 22331997).
Acute plasma exposure is brief; peak plasma concentration (Cmax ~86 mg/L) is reached ~1.5 hours after oral dosing and returns toward baseline within hours. Tissue taurine pools (heart, skeletal muscle) turn over much more slowly, so functional effects in trials are studied over days to weeks of repeated dosing rather than from a single dose.
Oral (dietary supplement, capsule/powder, or as an energy-drink ingredient). Route information is provided for monitoring and washout context, not to guide dosing or evade testing.
Taurine is largely not extensively metabolized; it is a metabolic end-product of cysteine metabolism, is used in bile-acid conjugation, and is cleared predominantly by renal excretion with tubular reabsorption that adjusts to intake. Apparent oral clearance/bioavailability ratio (Cl/F) ~21 L/h in healthy adults (PMID 22331997). Renal impairment could theoretically prolong exposure, but this has not been well characterized in humans.
For monitoring and washout planning, not drug-test evasion.
Physiological & performance effects
- Modest lowering of systolic and diastolic blood pressure in pooled randomized-trial data (SBP roughly -4 mmHg, DBP roughly -1.4 to -2.9 mmHg) (PMID 39148075, 32871172, 38755142).
- Small reduction in resting heart rate (~-3.6 bpm) and improvement in left-ventricular ejection fraction and NYHA class in heart-failure populations (PMID 39148075).
- Reductions in total cholesterol and triglycerides in patients with metabolic or liver dysregulation (PMID 32871172, 38755142).
- Modest reduction in fasting blood glucose in metabolic-syndrome populations (PMID 38755142).
- Anti-inflammatory and anti-atherogenic effects (lower C-reactive protein, improved atherogenic indices) around exercise in heart-failure patients (PMID 28580833).
- Improved resting vascular endothelial function (flow-mediated dilation) after 2 weeks at 6 g/day, without preventing exercise-induced endothelial dysfunction (PMID 31468418).
- Small ergogenic signal for aerobic/endurance and anaerobic performance, largely observed within caffeine-containing energy drinks where the benefit is confounded by caffeine and other ingredients (PMID 27757591, 36615738, 41032459). Standalone taurine benefit is modest and inconsistent.
Adverse effects by system
Taurine itself tends to lower blood pressure and heart rate rather than raise them; no significant adverse cardiovascular effects were seen versus placebo in RCT meta-analyses (PMID 39148075, 38755142). The relevant real-world hazard is that taurine is usually consumed in caffeine-containing energy drinks, where caffeine drives tachycardia, arrhythmia, and blood-pressure elevation; taurine's toxicity contribution in that setting is 'less well defined' (PMID 22426157). Additive hypotension/bradycardia with antihypertensive or rate-lowering drugs is plausible.
No evidence of hepatotoxicity in human trials; taurine has been studied as hepatoprotective and improved lipid markers in patients with liver dysregulation (PMID 32871172). No signal of liver injury at studied doses (PMID 18325648).
No human evidence that taurine suppresses or stimulates the hypothalamic-pituitary-gonadal axis; taurine is not a steroid or hormone and this is not an expected effect. No adequate human data specifically evaluating reproductive-hormone endpoints.
No adequate human data on fertility or pregnancy/lactation outcomes with supplemental taurine; safety in pregnancy and breastfeeding is not established.
No consistent adverse psychiatric effects attributable to taurine itself; taurine acts on GABA-A/glycine receptors and is generally not stimulating. In energy drinks, caffeine (not taurine) is associated with anxiety, insomnia, and exacerbation of psychiatric disease (PMID 22426157).
No demonstrated nephrotoxicity in healthy adults; clearance is primarily renal. Safety in significant chronic kidney disease has not been adequately studied and exposure could theoretically be prolonged (mechanistic inference from PMID 22331997; safety extrapolated from PMID 18325648).
No adverse hematologic effects reported; in heart-failure patients taurine was associated with reduced platelet count within normal handling and lower inflammatory markers, with no reported bleeding or cytopenia harms (PMID 28580833). No adequate data on clinically meaningful hematologic toxicity.
No known dermatologic adverse effects reported in the reviewed human literature; no adequate data specifically evaluating skin outcomes.
HPTA suppression & recovery
Suppression: None expected / no human evidence of HPTA suppression
Taurine is an amino acid, not an androgen, SERM, or hormonal agent, and there is no human evidence that it suppresses the hypothalamic-pituitary-gonadal axis, so no post-cycle recovery framework applies. Anyone using hormonal compounds alongside taurine, or with concerns about testosterone or fertility, should consult a qualified endocrinologist for individualized evaluation; do not rely on taurine for any HPTA-related purpose.
Monitoring
Cadence: Establish a baseline before starting; recheck blood pressure/heart rate within the first few weeks; repeat labs periodically (e.g., every few months) if using higher doses long-term or if combining with cardiovascular or glucose-lowering medication. Any dosing decisions and lab interpretation should be made with a clinician.
- Lightheadedness, fainting, or symptomatic low blood pressure (possible additive hypotension)
- Palpitations, irregular or very rapid heartbeat, or chest pain (usually caffeine-driven in energy drinks) - seek urgent care
- Hypoglycemia symptoms (shakiness, sweating, confusion) if combined with glucose-lowering therapy
- Insomnia, severe anxiety, agitation, or seizure - stop the product and seek care (caffeine-related)
- New or worsening swelling, reduced urine output, or signs suggesting kidney problems
Contraindications
- Concurrent use with antihypertensive or heart-rate-lowering medication without clinician oversight, given additive blood-pressure and heart-rate lowering.
- Consumption via high-caffeine energy drinks in people with cardiac arrhythmia, uncontrolled hypertension, or seizure disorder (risk is from caffeine, not taurine).
- Pregnancy and lactation, where supplemental (above-dietary) taurine safety is not established.
- Significant chronic kidney disease, where renal clearance may be altered and human safety data are inadequate.
- Combining energy drinks with alcohol, which is associated with increased risk-taking and impaired judgment.
- Known individual hypersensitivity to a taurine-containing product formulation.
Interaction profile
- ContraindicatedWith DNP: Additive cardiovascular strain
Check a specific combination in the interaction checker.
Reducing harm & when to stop
- Treat the energy-drink context as the main hazard: the cardiac, sleep, anxiety, and arrhythmia risks people attribute to 'taurine drinks' are largely from caffeine, not taurine (PMID 22426157). Track total caffeine, not just taurine.
- Do not combine taurine-containing energy drinks with alcohol; the combination is associated with impaired judgment and risky behavior (PMID 22426157).
- Because taurine can modestly lower blood pressure, heart rate, and glucose, be cautious if you take antihypertensive, heart-rate-lowering, or glucose-lowering medication, and involve a clinician before combining (PMID 39148075, 38755142).
- Human safety is best documented up to about 3 g/day; there is no reliable long-term human safety data above that, so higher intakes are not supported (PMID 18325648).
- Avoid supplemental (above-dietary) taurine in pregnancy, breastfeeding, and significant kidney disease, where human safety data are inadequate.
- Stop and seek medical care for fainting, palpitations, chest pain, seizure, severe anxiety/insomnia, or symptoms of low blood sugar.
- This monograph is educational harm-reduction information and does not recommend a dose or a stack; discuss any use with a qualified healthcare professional and get baseline and follow-up bloodwork.
Citations (11)
Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.
- 01
A formal risk assessment identified an Observed Safe Level of 3 g/day for supplemental taurine, with no systematic pattern of adverse effects in humans and no identifiable NOAEL/LOAEL; long-term safety above this level is not well established.
ReviewPMID 18325648 ↗
- 02
After a single 4 g oral dose in healthy adults, taurine reaches Cmax ~86 mg/L at ~1.5 h with a plasma elimination half-life of ~1.0 h and apparent clearance ~21 L/h, indicating short plasma exposure.
CohortPMID 22331997 ↗
- 03
Meta-analysis of 20 RCTs (808 participants) found taurine reduced heart rate (~-3.6 bpm), SBP (~-4.0 mmHg), and DBP (~-1.4 mmHg) and increased LVEF and NYHA class, with no significant adverse effects versus control.
Meta-analysisDOI 10.1186/s12937-024-00995-5 ↗
- 04
Meta-analysis of RCTs (doses 0.5-6 g/day) found taurine lowered SBP, DBP, total cholesterol, and triglycerides in patients with liver/metabolic dysregulation, without adverse effects on glucose or body weight.
Meta-analysisDOI 10.1016/j.ejphar.2020.173533 ↗
- 05
Meta-analysis of 25 RCTs (1024 participants; 0.5-6 g/day, 5-365 days) found taurine reduced SBP, DBP, fasting glucose, and triglycerides with no significant adverse effects versus control.
Meta-analysisDOI 10.1038/s41387-024-00289-z ↗
- 06
In an RCT in heart-failure patients, oral taurine 500 mg three times daily for 2 weeks reduced inflammatory (CRP, platelets) and atherogenic indices around exercise.
- 07
In a double-blind RCT, taurine 6 g/day for 2 weeks improved resting flow-mediated dilation (endothelial function) but did not prevent resistance-exercise-induced endothelial dysfunction.
- 08
In a meta-analysis of energy-drink trials, performance improvements were associated with taurine dose, though effects are confounded by caffeine and other co-ingredients.
Meta-analysisDOI 10.1007/s00394-016-1331-9 ↗
- 09
A systematic review/meta-analysis in female athletes reported taurine (with caffeine and beta-alanine) could improve aerobic test performance, but standalone taurine data were scarce.
Meta-analysisDOI 10.3390/nu15010081 ↗
- 10
A network meta-analysis found caffeine+taurine co-supplementation improved anaerobic capacity and reaction time versus either alone, with variable effects on endurance and physiological markers.
Meta-analysisDOI 10.1080/15502783.2025.2566371 ↗
- 11
In energy drinks, caffeine is the main driver of cardiovascular, psychiatric, and neurologic toxicity, and taurine's toxicity contribution is less well defined; alcohol co-ingestion increases risk-taking behavior.
Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice